These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1526680)

  • 21. Cefodizime given once daily for the treatment of upper urinary tract infections and complicated lower urinary tract infections.
    Hofstetter AG
    Infection; 1992; 20 Suppl 1():S18-21. PubMed ID: 1526670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A comparative study between cefodizime (CDZM) and cefotaxime (CTX) in respiratory tract infections].
    Takebe K; Imamura K; Masuda M; Murakami S; Tomiyama M; Tamura T; Endou K; Ishimaru K; Okushima T; Nakazono M
    Kansenshogaku Zasshi; 1989 Apr; 63(4):318-51. PubMed ID: 2506292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefotiam therapy of lower respiratory tract infections.
    Polis MA; Tuazon CU
    Antimicrob Agents Chemother; 1985 Oct; 28(4):576-7. PubMed ID: 3865632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of cefmenoxime in the pediatric infections].
    Meguro H; Ozawa S; Togo T; Hiraiwa M; Kim B; Fujii R
    Jpn J Antibiot; 1982 Oct; 35(10):2405-13. PubMed ID: 6306292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic study of cefodizime in experimentally infected animals.
    Arai S; Tabata S; Kobayashi S; Inazu M; Hayashi S
    Arzneimittelforschung; 1989 Aug; 39(8):877-82. PubMed ID: 2818675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections.
    Zuccotti GV; Trabattoni D; Morelli M; Borgonovo S; Schneider L; Clerici M
    J Biol Regul Homeost Agents; 2009; 23(2):119-23. PubMed ID: 19589293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Laboratory and clinical investigations of cefodizime in infectious diseases in childhood].
    Komada Y; Arai S; Kamiya H; Sakurai M; Shimizu S; Nishi H; Inoue M; Kojima M; Kawaguchi H; Yoshizumi T
    Jpn J Antibiot; 1989 Jun; 42(6):1346-57. PubMed ID: 2795858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum levels and sputum levels of cefmenoxime in respiratory tract infections].
    Matsumoto Y; Ninomaru S; Koshobu T; Ishikawa J; Nakatani S; Sasaki T
    Jpn J Antibiot; 1985 Jun; 38(6):1638-42. PubMed ID: 3862881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Laboratory and clinical studies of cefmenoxime in pediatric infections].
    Miyachi Y; Nakashima T; Aso K; Nishikawa K; Ogawa A; Yafuso M; Kuno K
    Jpn J Antibiot; 1982 Oct; 35(10):2459-67. PubMed ID: 6306297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical and pharmacokinetic study on cefodizime, a new cephalosporin antibiotic, in the pediatric infections].
    Arimasu O; Meguro H; Hiruma F; Sugie N; Abe T
    Jpn J Antibiot; 1989 Jun; 42(6):1293-305. PubMed ID: 2795854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cefodizime on non-specific immune functions in patients with multiple myeloma.
    Dammacco F; Benvestito S
    Infection; 1992; 20 Suppl 1():S64-6. PubMed ID: 1526682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological evaluation of cefodizime: a unique molecule among cephalosporins.
    Labro MT
    Infection; 1992; 20 Suppl 1():S45-7. PubMed ID: 1526677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open multicentre study of the efficacy and tolerance of cefodizime 1 g bd intravenously or intramuscularly in lower respiratory tract infections.
    Sollet JP
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():103-10. PubMed ID: 2074244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Laboratory and clinical studies of cefodizime in pediatric field].
    Nakao Y; Takeuchi H; Kimura H; Ishikawa H; Hayakawa F; Kuno K
    Jpn J Antibiot; 1989 Jun; 42(6):1336-45. PubMed ID: 2795857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of ceftriaxone.
    File TM; Tan JS; Salstrom SJ
    Clin Ther; 1984; 6(5):653-61. PubMed ID: 6090021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward a chronoimmunomodulation by cefodizime in multiple myeloma and chronic uremia.
    Carandente F; De Vecchi A; Halberg F; Cornélissen G; Dammacco F
    Chronobiologia; 1988; 15(1-2):61-85. PubMed ID: 3262046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of cefodizime.
    Andrassy K
    Infection; 1992; 20 Suppl 1():S36-40. PubMed ID: 1526675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefixime in the treatment of upper respiratory tract infections and otitis media.
    de Lalla F
    Chemotherapy; 1998 Sep; 44 Suppl 1():19-23. PubMed ID: 9797419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical experience with cefodizime in bacterial infection of children].
    Yokota I; Takeda E; Kuroda Y
    Jpn J Antibiot; 1989 Jun; 42(6):1385-90. PubMed ID: 2795862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.